Navigation Links
Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 2a clinical trial of JX-594 as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer that has spread to the liver.

The study is being led by Rebecca Auer, M.D., surgical oncologist at The Ottawa Hospital, associate scientist at the Ottawa Hospital Research Institute and assistant professor of surgery at the University of Ottawa in Ottawa, Canada.  The clinical trial is being supported by funding from the Ontario Institute for Cancer Research­.

"This trial will allow us to evaluate the use of JX-594 in patients with surgically resectable disease, potentially expanding the role of this therapy in the treatment continuum," said David H. Kirn, M.D., president and chief medical officer of Jennerex.  "We continue to believe that JX-594 could play an integral role in the treatment of cancers and look forward to the results of this trial along with data from the larger Phase 2b study, called TRAVERSE, that is under way in patients with advanced hepatocellular carcinoma."

"In addition, this study will allow us to expand our analysis of the multi-mechanistic therapeutic activity of JX-594 through the examination of tumor specimens collected during surgery following JX-594 administration," said John C. Bell, Ph.D., senior scientist, cancer therapeutics, Ottawa Hospital Research Institute, and professor of medicine, University of Ottawa.  Dr. Bell is also the program leader of the Ontario Institute for Cancer Research's Immuno- and Bio-therapies Program.

This Phase 2a clinical trial will enroll approximately 20 patients with colorectal cancer metastases to the liver. Patients will receive a single
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... /PRNewswire-iReach/ -- Phoenix Houses of California ... is hosting its tenth annual "Triumph For Teens" Awards ... 2013.  More than 300 people are expected to attend ... treatment centers, family therapy, and prevention programs of Phoenix ... positive influences on the health and welfare of our community ...
(Date:5/24/2013)... , May 24, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" ... specialty products, announced today that Dr. Robert Grieve ... Jason Napolitano , executive vice president and ... MicroCap Conference, which is being held May 30, 2013 in ... Hyatt Hotel. The Company,s presentation is scheduled ...
(Date:5/24/2013)... 24, 2013 In accordance with Rule 17.1 and ... of the United States Exchange Act, Echo Pharma Acquisition Limited ... Elan Corporation (NYSE: ELN). Background On ... an offer for the entire of the issued and to ... "Original Offer").  On 20 May 2013, Royalty ...
Breaking Medicine Technology:Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
(Date:5/24/2013)... May 24, 2013 Western University of ... status of “Full Accreditation” for the next seven years ... Education (COE). , “This is a magnificent achievement, and ... work and student outcomes,” said College of Veterinary Medicine ... my appreciation to the faculty, staff, preceptors, and students ...
(Date:5/24/2013)... With Memorial Day Weekend upon us, cookout season has officially ... to help prevent grill fires throughout the spring and summer. ... that gas grills led to an average of 7,100 home ... meanwhile, caused approximately 1,200 home fires per year during that ... the following tips from the NFPA to help protect your ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
(Date:5/24/2013)... Drugs commonly used to treat glaucoma may cause droopy ... vision, according to a new study. The drugs, ... reduce eye pressure, have already been shown to cause ... researchers said, suggesting that the new findings could lead ... be conservative when prescribing these drugs, the researchers added, ...
(Date:5/24/2013)... replicate what appeared to be breakthrough results for the ... last year in the journal Science . , ... the drug bexarotene (marketed as Targretin) could rapidly reverse ... pathological hallmark of Alzheimer,s disease in the brains ... report, drug treatment quickly removed most of the plaques ...
Breaking Medicine News(10 mins):Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3
... who suffer from bird-flu may require higher doses of Tamiflu, ... belonging to the World Health //Organization (WHO). If Tamiflu were ... the duration and severity of the illness can be reduced. ... to treat the H5N1, in anticipation of a flu pandemic. ...
... first face transplant recipient has undergone a further graft ... ,Isabelle Dinoire, 38, in Lyons, France, received a second ... same donor, which had been successful, doctors said. This ... rejecting the face. ,The technique was developed by ...
... New AIDS drugs produced by Pharmaceutical companies which are ... not available in Africa, where the actual benefit of ... (Doctors Without Border). MSF (Medicine sans Frontiers) have ... their new drugs in Africa. MSF is providing AIDS ...
... rats has shown that moderate exercise has positive benefits ... ,Several human studies in the last 10 to ... appear to harm people suffering from congestive heart failure. ... not been found to be statistically significant. ,In ...
... insulin led to the death of 62-year-old Moira Pullar on ... was administered by a nurse who failed to cross check// ... overdose of insulin resulted in bronchial pneumonia after cardiac arrest ... nurse was misread by another, leading to the fatal dose. ...
... for treatment of insomnia has no doubt prompted for invention ... best clinical// benefits according to a new review study conducted ... form the statement ‘Early to bed, early to rise makes ... who are deprived this wonderful gift, there are the new ...
Cached Medicine News:Health News:Dosage Of Tamiflu Sought To Be Increased 2Health News:Face transplant woman has new graft 2Health News:Newer Generation Sleeping Pills Lack Superior Performance 2
... fast and versatile automated strip washer which comes ... a self contained and programmable instrument. It allows ... the gentle dripping of a simple squeeze bottle ... ELx50/12V processes 1 x 12 strips or a ...
High precision microplate washer for immuno and adherent cell assays. For use with all strip types and full microplate in 96- and 384-well format in both portrait and landscape orientations....
The Wellwash 4 Mk 2 combines high performance and flexibility with reliability, simplicity and ease of use....
Synchron Hemoglobin A1c (HbA1c) utilizes two unique cartridges, Hb and A1c, to determine HbA1c concentration as a percentage of total hemoglobin....
Medicine Products: